pp-089 Injection
Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
Comments
Indication: Psoriasis requiring systemic immunomodulation.
Clinical stage: Phase 2a.
Modality: Antibody-inducing peptide vaccine.
Mechanism / Target: Induces neutralizing anti–IL-17A antibodies using AJP001 helper-T-cell epitope to activate B-cell responses.
Route / form: Subcutaneous injection.
Differentiation: Demonstrated dose-dependent antibody generation and good tolerability; offers vaccine-based IL-17A inhibition as an alternative to monoclonal antibodies.
Manufacturer #38644
A clinical-stage biotechnology firm advancing functional and antibody-inducing peptide medicines to address immune, skin and inflammatory conditions with aims to reduce patient burden versus traditional biologics. It builds on academic peptide technology with global R&D and strategic collaborations. The organization leverages peptide platforms for next-generation vaccines and therapeutic candidates.